Boston – October 30, 2026 -- Bambusa Therapeutics (Nasdaq: BBTX) priced its upsized initial public offering at $16.00 per share, raising expected gross proceeds of $168,888,880 from the sale of 10,555,555 common shares.
Underwriters hold a 30-day option on 1,583,333 additional shares
The clinical-stage biopharmaceutical company granted its underwriters the option to buy up to 1,583,333 more shares at the IPO price, less underwriting discounts and commissions. Bambusa is the sole seller; all shares in the offering come from the company. The gross figure is before underwriting discounts, commissions and other offering expenses.
Trading on Nasdaq Global Select Market begins October 30
Shares are expected to start trading on October 30, 2026, under the ticker BBTX. The offering is expected to close on November 2, 2026, subject to customary closing conditions.
BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are joint book-running managers. The registration statements were declared effective by the U.S. Securities and Exchange Commission on October 29, 2026. The preliminary prospectus was part of a Form S-1 filed on October 26, 2026.
Bispecific antibody pipeline spans two clinical and two preclinical programs
Bambusa develops long-acting bispecific antibodies for immunology and inflammation, formulated for high-concentration subcutaneous delivery. It aims to improve durability and convenience over existing monotherapies.
BBT001 targets IL-4Rα and IL-31 and is in clinical development for atopic dermatitis and other inflammatory skin diseases. BBT002 targets IL-4Rα and IL-5 and is in clinical development for Type 2 inflammatory disorders. Preclinical programs BBT003 and BBT004 focus on gastroenterology and autoantibody-driven autoimmune diseases, respectively.